Lichter M, Fleischner G, Kirsch R, Levi A J, Kamisaka K, Arias I M
Am J Physiol. 1976 Apr;230(4):1113-20. doi: 10.1152/ajplegacy.1976.230.4.1113.
Sephadex G-100 chromatography of rat liver supernatant after addition of [125I]T3 revealed four peaks of protein-bound radioactivity in the void volume, albumin, ligandin, and Z-containing regions, respectively. The peaks were identified by cochromatography of BSP and [125I]T3 and immonodiffusion with antiratligandin IgG and antirat Z IgG. Binding of [125I]T4 to rat liver supernatant occurred in void volume, albumin, and Z regions only. Studies in vivo reveal a pattern of [125I]T3 binding to rat liver supernatant fractions quantitatively different from that observed in vitro. [125I]T4 binding to liver supernatant fractions in vivo occurred in all four peaks. BSP or bilirubin added to liver supernatant decreased T3 and T4 binding by each fraction. Flavaspidic acid inhibited binding of T3 and T4 to albumin, ligandin, and Z protein. Phenobarbital pretreatment of rats increased binding of T3 by ligandin and of T4 by albumin-containing fractions. Circular dichroism studies with purified rat liver ligandin suggest that T3 and T4 bind competitively to the same site as does bilirubin; the association constants of T3 and T4 for ligandin are 10(6) and 10(5) M-1, respectively. T4 was bound only by purified ligandin and not by ligandin in liver supernatant. To determine whether unconjugated bilirubin interferes with hepatic uptake of T3, [125I]T3 was administered to icteric homozygous and phenotypically normal heterozygous Gunn rats. Hepatic uptake and supernatant binding [125I]T3 were significantly reduced in homozygous Gunn rats. Hepatic uptake of [125I]T3 was also reduced in vivo by infusion of BSP with or without flavaspidic acid. BSP infusion abolished [125I]T3 binding to ligandin; BSP and flavaspidic acid abolished binding to ligandin and Z. These observations suggest that ligandin and Z protein are thyroid hormone binding proteins in rat liver cytosol and may influence the net flux of iodothyronies from plasma into the liver.
添加[125I]T3后,对大鼠肝脏上清液进行葡聚糖凝胶G - 100层析,结果显示在空体积、白蛋白、配体结合蛋白和含Z蛋白区域分别出现四个蛋白质结合放射性峰。通过溴磺酚酞(BSP)与[125I]T3的共层析以及与抗大鼠配体结合蛋白IgG和抗大鼠Z IgG的免疫扩散鉴定这些峰。[125I]T4与大鼠肝脏上清液的结合仅发生在空体积、白蛋白和Z区域。体内研究显示,[125I]T3与大鼠肝脏上清液各组分的结合模式在数量上与体外观察到的不同。体内[125I]T4与肝脏上清液各组分的结合出现在所有四个峰中。添加到肝脏上清液中的BSP或胆红素降低了各组分对T3和T4的结合。黄绵马酸抑制T3和T4与白蛋白、配体结合蛋白和Z蛋白的结合。用苯巴比妥预处理大鼠可增加配体结合蛋白对T3的结合以及含白蛋白组分对T4的结合。对纯化的大鼠肝脏配体结合蛋白进行圆二色性研究表明,T3和T4与胆红素竞争结合同一部位;T3和T4与配体结合蛋白的缔合常数分别为10(6)和10(5) M-1。T4仅与纯化的配体结合蛋白结合,而不与肝脏上清液中的配体结合蛋白结合。为了确定未结合胆红素是否干扰肝脏对T3的摄取,给黄疸纯合子和表型正常的杂合子Gunn大鼠注射[125I]T3。纯合子Gunn大鼠肝脏对[125I]T3的摄取和上清液对[125I]T3的结合显著降低。在体内,无论有无黄绵马酸,输注BSP均可降低[125I]T3的肝脏摄取。输注BSP可消除[125I]T3与配体结合蛋白的结合;BSP和黄绵马酸可消除与配体结合蛋白和Z蛋白的结合。这些观察结果表明,配体结合蛋白和Z蛋白是大鼠肝细胞溶胶中的甲状腺激素结合蛋白,可能影响碘甲状腺原氨酸从血浆到肝脏的净通量。